- Home
- EDSA vs APLM Comparison
EDSA vs APLM Comparison
Compare EDSA & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- APLM
- Stock Information
- Founded
- EDSA 2015
- APLM 2016
- Country
- EDSA Canada
- APLM United States
- Employees
- EDSA N/A
- APLM N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- APLM Blank Checks
- Sector
- EDSA Health Care
- APLM Finance
- Exchange
- EDSA Nasdaq
- APLM Nasdaq
- Market Cap
- EDSA 13.8M
- APLM 6.9M
- IPO Year
- EDSA N/A
- APLM N/A
- Fundamental
- Price
- EDSA $2.04
- APLM $6.56
- Analyst Decision
- EDSA Strong Buy
- APLM
- Analyst Count
- EDSA 2
- APLM 0
- Target Price
- EDSA $13.00
- APLM N/A
- AVG Volume (30 Days)
- EDSA 14.6K
- APLM 6.5K
- Earning Date
- EDSA 08-08-2025
- APLM 08-13-2025
- Dividend Yield
- EDSA N/A
- APLM N/A
- EPS Growth
- EDSA N/A
- APLM N/A
- EPS
- EDSA N/A
- APLM N/A
- Revenue
- EDSA N/A
- APLM $198,000.00
- Revenue This Year
- EDSA N/A
- APLM $415.15
- Revenue Next Year
- EDSA N/A
- APLM N/A
- P/E Ratio
- EDSA N/A
- APLM N/A
- Revenue Growth
- EDSA N/A
- APLM N/A
- 52 Week Low
- EDSA $1.55
- APLM $4.47
- 52 Week High
- EDSA $5.59
- APLM $35.98
- Technical
- Relative Strength Index (RSI)
- EDSA 52.18
- APLM 53.03
- Support Level
- EDSA $1.99
- APLM $6.21
- Resistance Level
- EDSA $2.14
- APLM $6.80
- Average True Range (ATR)
- EDSA 0.12
- APLM 0.50
- MACD
- EDSA 0.02
- APLM 0.02
- Stochastic Oscillator
- EDSA 58.62
- APLM 77.22
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.